Emergent BioSolutions Inc. (EBS) stock
EBSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/3072% below fair value
$5.89−0.15 (-2.48%)
Close on Nov 12, 2026Market cap $302.00MP/E –Yield –
Emergent BioSolutions profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Emergent BioSolutions's profit margin for the twelve months ending Sep 30, 2026 was -40.2%. For fiscal 2025 it was 7.1%, against -18.3% the year before. The highest annual figure on record is 19.4% in fiscal 2020.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 7.1% | +25.3 |
| FY2024 | Dec 31, 2024 | -18.3% | +54.2 |
| FY2023 | Dec 31, 2023 | -72.5% | −53.5 |
| FY2022 | Dec 31, 2022 | -18.9% | −31.3 |
| FY2021 | Dec 31, 2021 | 12.4% | −7.0 |
| FY2020 | Dec 31, 2020 | 19.4% | +14.5 |
| FY2019 | Dec 31, 2019 | 4.9% | −3.1 |
| FY2018 | Dec 31, 2018 | 8.0% | −6.7 |
| FY2017 | Dec 31, 2017 | 14.7% | +4.1 |
| FY2016 | Dec 31, 2016 | 10.6% | −2.3 |
| FY2015 | Dec 31, 2015 | 12.8% | +3.8 |
| FY2014 | Dec 31, 2014 | 9.1% | −0.9 |
| FY2013 | Dec 31, 2013 | 10.0% | +1.6 |
| FY2012 | Dec 31, 2012 | 8.3% | −0.1 |
| FY2011 | Dec 31, 2011 | 8.4% | −9.6 |
| FY2010 | Dec 31, 2010 | 18.1% | +4.8 |
| FY2009 | Dec 31, 2009 | 13.3% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -29.7% | −51.9 |
| Q2 FY2026 | Jun 30, 2026 | -76.9% | −68.4 |
| Q1 FY2026 | Mar 31, 2026 | 4.4% | −26.2 |
| Q4 FY2025 | Dec 31, 2025 | -36.7% | −20.6 |
| Q3 FY2025 | Sep 30, 2025 | 22.2% | −16.9 |
| Q2 FY2025 | Jun 30, 2025 | -8.5% | +102.6 |
| Q1 FY2025 | Mar 31, 2025 | 30.6% | +27.6 |
| Q4 FY2024 | Dec 31, 2024 | -16.1% | +1.8 |
| Q3 FY2024 | Sep 30, 2024 | 39.1% | +136.4 |
| Q2 FY2024 | Jun 30, 2024 | -111.2% | −33.8 |
| Q1 FY2024 | Mar 31, 2024 | 3.0% | +116.3 |
| Q4 FY2023 | Dec 31, 2023 | -17.9% | +2.4 |
| Q3 FY2023 | Sep 30, 2023 | -97.4% | −61.1 |
| Q2 FY2023 | Jun 30, 2023 | -77.4% | −55.6 |
| Q1 FY2023 | Mar 31, 2023 | -113.3% | −111.8 |
| Q4 FY2022 | Dec 31, 2022 | -20.3% | −46.6 |
| Q3 FY2022 | Sep 30, 2022 | -36.3% | −22.2 |
| Q2 FY2022 | Jun 30, 2022 | -21.8% | −21.7 |
| Q1 FY2022 | Mar 31, 2022 | -1.5% | −19.4 |
| Q4 FY2021 | Dec 31, 2021 | 26.3% | −5.5 |
| Q3 FY2021 | Sep 30, 2021 | -14.1% | −24.4 |
| Q2 FY2021 | Jun 30, 2021 | -0.1% | −23.6 |
| Q1 FY2021 | Mar 31, 2021 | 17.9% | +24.3 |
| Q4 FY2020 | Dec 31, 2020 | 31.8% | +18.8 |
| Q3 FY2020 | Sep 30, 2020 | 10.3% | −3.6 |
| Q2 FY2020 | Jun 30, 2020 | 23.5% | +27.4 |
| Q1 FY2020 | Mar 31, 2020 | -6.5% | +7.2 |
| Q4 FY2019 | Dec 31, 2019 | 13.0% | +14.3 |
| Q3 FY2019 | Sep 30, 2019 | 13.9% | +1.8 |
| Q2 FY2019 | Jun 30, 2019 | -3.9% | −26.7 |
| Q1 FY2019 | Mar 31, 2019 | -13.7% | −9.5 |
| Q4 FY2018 | Dec 31, 2018 | -1.3% | −18.8 |
| Q3 FY2018 | Sep 30, 2018 | 12.0% | −10.4 |
| Q2 FY2018 | Jun 30, 2018 | 22.8% | +18.2 |
| Q1 FY2018 | Mar 31, 2018 | -4.2% | −13.1 |
| Q4 FY2017 | Dec 31, 2017 | 17.5% | −7.2 |
| Q3 FY2017 | Sep 30, 2017 | 22.5% | – |
| Q2 FY2017 | Jun 30, 2017 | 4.6% | – |
| Q1 FY2017 | Mar 31, 2017 | 9.0% | – |
| Q4 FY2016 | Dec 31, 2016 | 24.7% | – |
See a number that looks wrong?